| Document |
Document Title |
|
WO/2023/229366A1 |
The present invention provides surface-engineered extracelluar vesicles, compositions comprising the surface-engineered extracelluar vesicles, methods for preparing the surface-engineered extracelluar vesicles, and methods for using the ...
|
|
WO/2023/229819A1 |
The present disclosure is directed to methods of producing oligodendrocyte progenitor cells (OPCs). In addition, methods of treating demyelinating diseases using oligodendrocyte progenitor cells (OPCs) are also disclosed.
|
|
WO/2023/228182A1 |
This invention discloses a three-dimensional (3D) bioreactor for large scale expansion of immune cells and methods of use. The 3D bioreactor comprising at least one packed bed chamber comprising at least one porous scaffold; at least one...
|
|
WO/2023/229286A1 |
The present invention relates to a method for making various organoid combinations by selecting frozen tumor organoid columns on the basis of genetic information, and analyzing drugs by using same. Particularly, the present invention rel...
|
|
WO/2023/230568A2 |
Disclosed herein are methods of generating hypoimmunogenic cells and methods of using hypoimmunogenic cells for treating mammalian diseases and for preparing biomimetic nanovesicles (BioNVs).
|
|
WO/2023/230581A1 |
The present disclosure provides cell populations enriched for CD28 positive T cells, and methods for stimulating, genetically engineering, and/or cultivating such cell populations. Also included are methods for generating, isolating, enr...
|
|
WO/2023/230316A1 |
The disclosure features compositions, systems, and methods for preparation and use of efficient RNA nuclear export of ribozyme-assisted circular RNA molecules (racRNAs). In embodiments, the methods involve characterizing a cell or tissue...
|
|
WO/2023/230272A1 |
The present disclosure provides transposon-based systems for introducing cellular therapeutic products, such as CAR and TCR, into a target immune cell. The transposon-based systems can carry larger pay loads than conventional viral vecto...
|
|
WO/2023/223291A1 |
The present disclosure provides improved methods of producing engineered immune cells (e.g., CAR-T cells). The resulting engineered immune cells and compositions comprising the same are useful in treating various diseases, e.g., infectio...
|
|
WO/2023/223666A1 |
Provided is a cell culture device 1 comprising: a lower substrate 10 that includes a cell culture part 14 having a bottom membrane; and an upper substrate 12 that is provided above the lower substrate 10 and that includes a cell housing ...
|
|
WO/2023/223519A1 |
The present invention relates to a deactivating agent for activated hepatic stellate cells, said deactivating agent including a transforming proliferative factor β/bone morphogenetic protein signal inhibitor, an activin receptor-like ki...
|
|
WO/2023/221988A1 |
The present application discloses use of nano layered double hydroxides in cartilage regeneration and a method for preparing same, and particularly, discloses use of nano layered double hydroxides in promoting chondrogenic differentiatio...
|
|
WO/2023/221241A1 |
Provided are a baculovirus vector and use thereof in the preparation of rAAV in an insect cell. The baculovirus vector comprises an exogenous gene expression cassette and a stable sequence, the stable sequence being located within 5 kb a...
|
|
WO/2023/225687A1 |
Methods of growing cells in a serum-free culture media are provided, in particular methods for expansion of the number of cells. The disclosed methods use media that can include a baseline serum-free and animal component-free culture med...
|
|
WO/2023/225485A1 |
Embodiments of the disclosure concern polyclonal virus specific T cell lines and methods of using the same to treat BK viremia in kidney transplant recipients.
|
|
WO/2023/221853A1 |
Disclosed in the present invention are a method for constructing a senescent cell and a method for evaluating the anti-senescence efficacy. The method for constructing the senescent cell comprises: performing seeding culture and subcultu...
|
|
WO/2023/222875A1 |
The present invention refers to an in vitro or ex vivo method for the treatment of isolated CD8+ T cells. In particular, it refers to an in vitro or ex vivo method for obtaining an isolated population of CD8+ T cells comprising exposing ...
|
|
WO/2023/224599A1 |
Embodiments of the disclosure concern polyclonal virus specific T cell lines and methods of using the same to treat BK viremia in kidney transplant recipients.
|
|
WO/2023/223520A1 |
The present invention relates to a screening method for substances that deactivate activated hepatic stellate cells, said method including a step in which activated hepatic stellate cells and a test substance are brought into contact wit...
|
|
WO/2023/221438A1 |
Provided is a method for promoting differentiation of iPSC into an islet cell by means of regulating NGN3 expression. The method promotes the differentiation of iPSC into the islet cell by means of adding recombinant human activin A at a...
|
|
WO/2023/224431A1 |
The present invention relates to a pharmaceutical composition comprising, as an active ingredient, hypothalamus-like organoid-derived neural stem cells for preventing and treating geriatric diseases. It was found that decreased memory, c...
|
|
WO/2023/222040A1 |
The present invention relates to a recombinant erythropoietin, a nucleic acid molecule encoding same, a fusion protein comprising same, an expression vector, host cell and composition thereof, and an application thereof. The recombinant ...
|
|
WO/2023/221418A1 |
Provided are an induction method for promoting the conversion of pancreatic islet α cells into β cells and use thereof. According to the induction method, on the basis of a traditional induction method, on the 35th day of induced diffe...
|
|
WO/2023/223292A1 |
The present disclosure provides improved methods of producing engineered T cells that express an exogenous gene (e.g., CAR-T cells). T cells that express an exogenous gene and compositions comprising the same of the present technology ar...
|
|
WO/2023/223303A1 |
The present invention provides a method to obtain unique cell lines for various applications and systems and methods for a machine learning/AI/Deep Learning software platform that supports the development and optimization of functional i...
|
|
WO/2023/224099A1 |
The cell culture substrate according to the present invention is provided with at least one well having a side surface and a bottom surface, in which the side surface includes a first side part that defines a first space and a second sid...
|
|
WO/2023/223083A1 |
A cultured meat production process comprising the steps of: a) mixing a first cell-loaded cross-linkable edible gel material with a second non-cross-linkable gel material to obtain a cell-gel mixture; b) letting the cell-gel mixture drop...
|
|
WO/2023/225686A1 |
A serum-free culture media for expansion of the number of cells is disclosed. The disclosed media can be for use in cultured food applications. The disclosed media can include a baseline serum-free and animal component-free culture media...
|
|
WO/2023/223185A1 |
The present disclosure provides ex vivo methods which employ modified cells of leukemic origin to enhance the efficacy of adoptive cell therapy with natural killer (NK) cells.
|
|
WO/2023/223447A1 |
The present invention provides: a prediction device and prediction method for predicting the future differentiation level of cultured cells before induction of differentiation on the basis of the miRNA content of the exosomes of the cult...
|
|
WO/2023/221565A1 |
Provided are a method for differentiating an induced pluripotent stem cell into a pancreatic islet and use thereof in treating type I diabetes mellitus. By adopting the method, the induced differentiation efficiency of differentiating th...
|
|
WO/2023/220815A1 |
The present disclosure provides a novel lipid nanoparticle (LNP) compositions useful for the transfection and expression of exogenous proteins in platelet cells. In particular, wherein the LNP composition comprises mRNA encoding the exog...
|
|
WO/2023/221938A1 |
The present invention provides a protein-encapsulated self-replicating RNA and a preparation method therefor. The protein-encapsulated self-replicating RNA is obtained by culturing recombinant cells. A recombinant cell comprises: a first...
|
|
WO/2023/222842A1 |
The device comprises a substrate comprising a first zone (1) on which is absorbed a protein capable of binding to a first membrane molecule and comprising a second zone (2), on which an antibody is absorbed, targeting a second membrane m...
|
|
WO/2023/225293A1 |
Methods for identifying, isolating and enriching neural stem and progenitor cells (NSPC) such as ventricular radial glia, outer radial glia, astrocytes, pre-oligodendrocyte precursor cells, oligodendrocyte precursor cells, oligodendrocyt...
|
|
WO/2023/224556A1 |
The present invention relates to methods of rejuvenating aged oocytes using young somatic cells through the generation of chimeric follicles. The chimeric follicles defined herein may be used to treat infertility or improve fertility in ...
|
|
WO/2023/225594A1 |
Chondrogenic potential of mesenchymal stem cells (MSCs) can be determined using magnetic resonance relaxometry by measuring T2 relaxation value of the MSCs.
|
|
WO/2023/224096A1 |
The present invention addresses the problem of providing a cancer vaccine that uses a common cancer antigen cocktail, a TCR/CAR-T cell therapeutic, a companion diagnostic method, and a method for diagnosing cancer onset risk by blood-cir...
|
|
WO/2023/221959A1 |
Provided in the present application is a T cell receptor (TCR) having a property of binding to a GVYDGREHTV-HLA A0201 complex. Also provided in the present application are a multivalent TCR complex, a nucleic acid molecule encoding such ...
|
|
WO/2023/224484A1 |
A method of forming a hydrogel fibre inside a bioreactor is provided. The method comprises steps of providing a container vessel of the bioreactor with a volume of cross-linking fluid therein, and injecting a flow of hydrogel precursor f...
|
|
WO/2023/225608A1 |
NEO-201, an antibody that specifically binds to glycosylated peptides carrying core-1 and/or extended core-1 O-glycans comprised in CEACAM5 and CEAMCAM6 but not to aglycosylated CEACAM5 or aglycosylated CEAMCAM6 surprisingly has been sho...
|
|
WO/2023/220793A1 |
The present invention relates to a method for screening potentially neuroprotective pharmaceuticals or substances. The present invention further relates to a kit for screening potentially neuroprotective pharmaceuticals or substances.
|
|
WO/2020/117508A9 |
Embodiments of the invention include a system having a plant stem cell product and a delivery device configured to deliver an effective amount of the plant stem cell product to the oral cavity or nasopharynx. In some embodiments, the del...
|
|
WO/2023/221554A1 |
Disclosed in the present invention are an herbicide-resistant transgenic corn event nCX-1, a nucleic acid sequence and a detection method therefor. The nucleic acid molecule of the transgenic corn event nCX-1 is a DNA molecule obtained b...
|
|
WO/2023/225665A1 |
The present disclosure provides polynucleotides that are capable of reducing the level of a NR4A3 gene and/or NR4A3 protein in a cell (e.g., immune cell). In some aspects, the polynucleotides comprises a gRNA that specifically targets a ...
|
|
WO/2023/221240A1 |
Provided are a composition and a method for generating a recombinant baculovirus in an insect cell, and use. The composition comprises a packaging-deficient baculovirus plasmid and a first rescue recombinant DNA. The packaging-deficient ...
|
|
WO/2023/217126A1 |
Provided in the present invention is a method for preparing a renal epithelial precursor-like cell, comprising the following steps: providing primary renal cells, placing the primary renal cells into a reprogramming medium for dedifferen...
|
|
WO/2023/217145A1 |
The present application discloses a use of an antigen short peptide in the screening of a drug for treating an HPV-related disease, and a T cell receptor (TCR) screened by the antigen short peptide. An amino acid sequence of the antigen ...
|
|
WO/2023/216341A1 |
A method for preparing a biological age reversing preparation, comprising the steps of: placing cytotoxic T lymphocytes, a cell mitogen, a cytokine, and an immune adjuvant in a liquid cell culture medium in a culture container for co-cul...
|
|
WO/2023/218789A1 |
The present invention pertains to a method for collecting stem cells from animal tissue, the method comprising a step in which at least a surface of the animal tissue is made to contact a cleaning liquid, wherein the cleaning liquid is a...
|
